Skip to main content

DBV Technologies S.A.

DBVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001613780

In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.

Other share classesDBVTF

Q3 2025 vs. Q2 2025

How the institutions holding DBV Technologies S.A. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of DBVT: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders2933+4
Shares7.23M6.52M−713.4K (−9.9%)
Value$66.2M$65.2M−$1.03M (−1.6%)

New holders (8)

Institutions that held DBV Technologies S.A. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to DBVT in Q3 2025
InstitutionSharesValue% of portfolio
Artisan Partners Limited Partnership51,920$519.2K0.00%
DLD Asset Management, LP25,000$250.0K0.03%
Citadel Advisors LLC22,049$220.5K0.00%
Two Sigma Investments, LP16,682$166.8K0.00%
New York State Common Retirement Fund3,420$34.2K0.00%
Toronto Dominion Bank320$3.20K0.00%
Advisory Services Network, LLC130$1.30K0.00%
BlackRock, Inc.2$200.00%

Sold out (4)

Institutions that held DBV Technologies S.A. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of DBVT in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
MYDA Advisors LLC30,220$276.8K
Point72 Asset Management, L.P.17,000$155.7K
Steward Partners Investment Advisory, LLC1,518$13.9K
Raymond James Financial Inc916$8.39K